Prilactone Next

3 x 10 pc

Chewable tablet

Active substance

Spironolactone : 50 mg

ATC code

QC03DA01 Spironolactone

QC03DA Aldosterone antagonists

QC03D Potassium-sparing agents

QC03 Diuretics

QC Cardiovascular system

Species

Dogs

Indications

For use in combination with standard therapy (including diuretic support, where necessary) for the treatment of congestive heart failure caused by degenerative mitral valve disease in dogs.

Dose to be administered and administration route

2 mg of spironolactone per kg of body weight once daily, i.e. 1 tablet per 25 kg of body weight, by oral route. The product should be administered with meal.

Dog weight (kg)	Prilactone Next 50 mg Number of tablets per day
> 3.0 to 6.0	¼
> 6.0 to 12.5	½
> 12.5 to 18.0	¾
> 18.0 to 25.0	1
> 25.0 to 31.0	1 ¼
> 31.0 to 37.0	1 ½
> 37.0 to 43.0	1 ¾
> 43.0 to 50.0	2

The tablets are flavoured. If the dog does not accept the tablet from hand or bowl, then the tablets may be mixed with a small amount of food offered prior to the main meal, or administered directly into the mouth after feeding.

Instruction on how to divide the tablet: Put the tablet on an even surface, with its scored side facing down (convex face up). With the tip of the forefinger, exert slight vertical pressure on the middle of the tablet to break it along its width into halves.

Then, in order to obtain quarters, exert slight pressure on the middle of one half with the forefinger to break it into two parts.

Adverse reactions

Very common

(>1 animal / 10 animals treated):

Prostatic atrophy¹

Common

(1 to 10 animals / 100 animals treated):

Vomiting, Diarrhoea

¹in entire male dogs, reversible

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.